A total of 139 young stroke patients were consecutively examined and tested for antiphospholipid antibodies (APLA) to evaluate the role of these antibodies in cerebral ischaemia before the age of 45. APLA were found in 28.8% of patients. Two factors, hypertriglyceridaemia and alcohol abuse, were significantly more frequent in patients with a positive APLA test. The demographic characteristics, other risk factors, history of prior thrombotic events and distribution of aetiopathogenic types of cerebral ischaemia were not different in patients with or without APLA. Laboratory assays for APLA were highly positive for only two patients, who both had autoimmune diseases. These results suggest that with the exception of a clinical context of antiphospholipid syndrome or other autoimmune diseases, the usefulness of this diagnostic tool in the management of cerebral ischaemia remains limited.

Keywords:
Antiphospholipid antibodies, Cerebral ischaemia, Young adults
1.
Harris EN, Gharavi AE, Boey ML, Asherson RA, Hughes GRV: Cerebral infarction in systemic lupus: Association with anticardiolipin antibodies. Clin Exp Rheumatol 1984;2:47–51.
2.
Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. The Antiphospholipid Antibodies in Stroke Study Group. Stroke 1990;21:1268–1273.
3.
Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Neurology 1993;43:2069–2073.
4.
Tuhrim S, Rand J, Wu X-X, Weinberger J, Horowitz D, Goldman M, Godbold J: Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999;30:1561–1565.
5.
Stroke –1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke 1989;20:1407–1431.
6.
Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988;8(suppl 7):1–96.
7.
Johnson CJ, Kittner SJ, McCarter RJ, Sloan MA, Stern BJ, Buchholz D, Price TR: Interrater reliability of an etiologic classification of ischemic stroke. Stroke 1995;26:46–51.
8.
Goudemand J, Caron C, De Prost D, Derlon A, Borg J-Y, Sampol J, Sié P: Evaluation of sensitivity and specificity of a standardized procedure using different reagents for the detection of lupus anticoagulants. The Working Group on Hemostasis of the Société Française de Biologie Clinique and for the Groupe d’Etudes sur I’Hémostase et la Thrombose. Thromb Haemost 1997;77:336–342.
9.
Comparison of a standardized procedure with current laboratory practices for the detection of lupus anticoagulant in France. Working Group on Hemostasis of the Société Française de Biologie Clinique. Thromb Haemost 1993;70:781–786.
10.
Harris EN: Special report. The Second International Anti-Cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 1990;94:476–484.
11.
Jouhikainen T, Stephansson E, Leirisalo-Repo M: Lupus anticoagulant as a prognostic marker in systemic lupus erythematosus. Br J Rheumatol 1993;32:568–573.
12.
Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, Fernandez L, Ponce de Leon S: Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989;68:353–365.
13.
Piette JC: What is going to happen tomorrow regarding the antiphospholipid syndrome? Jean-Charles Piette. Ann Med Interne (Paris) 1995;146:555–558.
14.
Nencini P, Baruffi MC, Abbate R, Massai G, Amaducci L, Inzitari D: Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 1992;23:186–193.
15.
Brey RL, Hart RG, Sherman DG, Tegeler CH: Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990;40:1190–1196.
16.
Munts AG, Van Genderen PJ, Dippel DW, Van Kooten F, Koudstaal PJ: Coagulation disorders in young adults with acute cerebral ischaemia. J Neurol 1998;245:21–25.
17.
Love PE, Santoro SA: Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990;112:682–698.
18.
Triplett DA: Frequent difficulties encountered in the laboratory diagnosis of antiphospholipid-protein antibodies. Ann Med Interne (Paris) 1996;147(suppl 1):5–9.
19.
Nencini P, Baruffi MC, Abbate R, Massai G, Amaducci L, Inzitari D: Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 1992;3:186–193.
20.
Guerin J, Feighery C, Sim RB, Jackson J: Antibodies to beta2-glycoprotein I: A specific marker for the antiphospholipid syndrome. Clin Exp Immunol 1997;109:304–309.
21.
Alving BM, Barr CF, Tang DB: Correlation between lupus anticoagulants and anticardiolipin antibodies in patients with prolonged activated partial thromboplastin times. Am J Med 1990;88:112–116.
22.
Trimble M, Bell DA, Brien W, Hachinski V, O’Keefe B, McLay C, Black J: The antiphospholipid syndrome: Prevalence among patients with stroke and transient ischemic attacks. Am J Med 1990;88:593–597.
23.
Harris EN: Antiphospholipid antibodies. Br J Haematol 1990;74:1–9.
24.
Levine SR, Welch KM: Cerebrovascular ischemia associated with lupus anticoagulant. Stroke 1987;18:257–263.
25.
Levine SR, Welch KM: The spectrum of neurological disease associated with antiphospholipid antibodies. Arch Neurol 1987;44:876–883.
26.
Kushner M, Simonian N: Lupus anticoagulant, anticardiolipin antibodies, and cerebral ischemia. Stroke 1989;20:225–229.
27.
Laraki R, Blétry O, Wechsler B, Piette JC, De Zuttere D, Godeau P: Cœur et anticorps antiphospholipides. Expérience personnelle et revue de la littérature. Rev Med Interne 1996;17:46–57.
28.
Laraki R, Blétry O, Horellou MH: Corrélations entre anticorps antiphospholipides et lésions neurologiques centrales ou cardiaques. Rev Med Interne 1990;11:S285.
29.
Amigo MC, Garcia-Torres R, De la Rosa A, Reyes A: Histopathologic characterization of valvular damage in the primary antiphospholipid syndrome. Arthritis Rheum 1994;37:S176.
30.
Levine SR, Salowich-Palm L, Sawaya KL, Perry M, Spencer HJ, Winkler HJ, Alam Z, Carey JL: IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death: A prospective cohort study. Stroke 1997;28:1660–1665.
31.
Levine SR, Brey RL, Sawaya KL, Salowich-Palm L, Fiffinos J, Korstrzema B, Perry M, Havstad S, Carey J: Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol 1995;38:119–124.
32.
Levine SR, Deegan MJ, Futrell N, Welch KMA: Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990;40:1181–1189.
33.
Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J, Outt HH, Harris EN, Vilardell-Torres M, Hughes GR: The ‘primary’ antiphospholipid syndrome: Major clinical and serological features. Medicine (Baltimore) 1989;68:366–374.
34.
Borba EF, Bonfa E: Dyslipoproteinemias in systemic lupus erythematosus: Influence of disease, activity, and anticardiolipin antibodies. Lupus 1997;6:533–539.
35.
Palomäki H, Kaste M: Regular light to moderate intake of alcohol and the risk of ischemic stroke. Stroke 1993;24:1828–1832.
36.
Feldmann E, Levine SR: Cerebrovascular disease with antiphospholipid antibodies: Immune mechanisms, significance, and therapeutic options. Ann Neurol 1995;37:S114–S130.
37.
Laraki R, Blétry O, Piette JC, Godeau P: Le syndrome des antiphospholipides. Sang Thrombose Vaisseaux 1991;3:363–369.
38.
Hughes GRV, Harris NN, Gharavi AE: The anticardiolipin syndrome. J Rheumatol 1986;13:486–489.
39.
Alarcon-Segovia D, Sanchez-Guerrerro J: Primary antiphospholipid syndrome. J Rheumatol 1989;16:482–488.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.